Overview

Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
PQ-504a-001 (Fuchs Focus) is an open-label, single-dose, exploratory study to evaluate safety, tolerability, and corneal endothelium molecular biomarker(s) in subjects with Fuchs Endothelial Corneal Dystrophy with Trinucleotide Repeat Expansion in the TCF4 gene (FECD3).
Phase:
Phase 1
Details
Lead Sponsor:
ProQR Therapeutics